Compounds, compositions, methods, and kits relating to telomere extension

Patent metadata

Field	Value
Publication number	US-11007210-B2
Application number	US-202016735681-A
Country	US
Kind code	B2
Filing date	Jan 6, 2020
Priority date	Feb 22, 2013
Publication date	May 18, 2021
Grant date	May 18, 2021

Abstract

Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.

First claim

What is claimed is:

1. A method of extending telomeres, comprising the step of:
administering a compound to an animal cell,
wherein the administering is in vivo,
wherein the compound comprises a synthetic ribonucleic acid comprising at least one modified nucleoside and coding for a telomerase reverse transcriptase,
wherein the telomerase reverse transcriptase is expressed transiently in the cell, and
wherein at least one telomere is extended within the cell.

2. The method of claim 1 , wherein the cell has at least one shortened telomere prior to the administering step.

3. The method of claim 1 , wherein the cell is in a subject suffering from or at risk of an age-related illness, an age-related condition, or an age-related decline in function or appearance.

4. The method of claim 1 , wherein the cell is in a subject suffering from or at risk of cancer, heart disease, stroke, diabetes, diabetic ulcers, Alzheimer's disease, osteoporosis, a decline in physical ability or appearance, physical trauma or chronic physical stress, psychological trauma or chronic psychological stress, reduced immune function, immunosenescence, or macular degeneration.

5. The method of claim 1 , wherein the cell is a somatic cell of endodermal, mesodermal, or ectodermal lineage, or a germ line or embryonic cell.

6. The method of claim 1 , wherein the cell is a transdifferentiated cell or a cell used to produce a transdifferentiated cell.

7. The method of claim 1 , wherein the administering step increases telomerase activity in the cell.

8. The method of claim 7 , wherein the telomerase activity is transiently increased by at least 5%.

9. The method of claim 7 , wherein the half-life of increased telomerase activity is no longer than 48 hours.

10. The method of claim 7 , wherein the half-life of increased telomerase activity is at least 2 hours.

11. The method of claim 1 , wherein the method further comprises the step of measuring telomere length in the cell.

12. The method of claim 1 , wherein the administering step increases average telomere length in the cell.

13. The method of claim 12 , wherein average telomere length in the cell is increased by at least 0.1 kb.

14. The method of claim 1 , wherein the administering step increases population doubling capacity in the cell.

15. The method of claim 14 , wherein the population doubling capacity increases by at least one population doubling.

16. The method of claim 1 , wherein the cell is in a mammalian subject.

17. The method of claim 16 , wherein the cell is in a human subject.

18. The method of claim 1 , wherein the at least one telomere is transiently extended within the cell.

19. The method of claim 1 , wherein the telomerase reverse transcriptase is a mammalian, avian, reptilian, or fish telomerase reverse transcriptase or a variant that retains telomerase catalytic activity.

20. The method of claim 19 , wherein the telomerase reverse transcriptase is a human telomerase reverse transcriptase.

21. The method of claim 1 , wherein the method comprises the step of administering a composition to the animal cell, wherein the composition comprises the compound and a delivery vehicle, and wherein the delivery vehicle comprises an exosome, a lipid nanoparticle, a polymeric nanoparticle, a natural or artificial lipoprotein particle, a cationic lipid, a protein, a protein-nucleic acid complex, a liposome, a virosome, or a polymer.

22. The method of claim 21 , wherein the delivery vehicle comprises a nanoparticle.

23. The method of claim 1 , wherein the composition is administered by injection, topical application, or inhalation.

Assignees

• Univ Leland Stanford Junior

Inventors

• Ramunas John
• Yakubov Eduard
• Blau Helen M
• Cooke John

Classifications

• C12Y207/07049

  RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase · CPC title

• C12N15/52

  Genes encoding for enzymes or proenzymes · CPC title

• C12N9/1276

  RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P31/16

  for influenza or rhinoviruses · CPC title